Delcasertib hydrochloride KAI-9803 hydrochloride; BMS-875944 hydrochloride|西域试剂

Delcasertib hydrochloride KAI-9803 hydrochloride; BMS-875944 hydrochloride,98.11%

产品编号：Bellancom-106262B| 分子式：C₁₂₀H₂₀₀ClN₄₅O₃₄S₂| 分子量：2916.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-106262B		￥6500.00	杭州北京（现货）
Bellancom-106262B		￥9900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Delcasertib hydrochloride KAI-9803 hydrochloride; BMS-875944 hydrochloride

产品介绍

Delcasertib (KAI-9803) hydrochloride 是有效，选择性的 δ 蛋白激酶C (δPKC) 抑制剂。Delcasertib (KAI-9803) hydrochloride 可改善急性心肌梗死动物模型的缺血再灌注损伤。

生物活性

Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).

体外研究

Delcasertib (KAI-9803) is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide derived from the δV1-1 portion of δPKC (termed “cargo peptide”), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47–57; termed “carrier peptide”) via a disulfide bond.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Delcasertib (KAI-9803, a single intraperitoneal injection) in mice results in the selective inhibition of PKC translocation in the liver, kidney, lung, heart, and brain.
Delcasertib (KAI-9803) administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction.
Delcasertib (KAI-9803) has been studied for the prevention of reperfusion injury in patients undergoing angioplasty after acute myocardial infarction.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old male Crl:CD(SD) rats
Dosage:	1 mg/kg (Pharmacokinetic Analysis).
Administration:	Via the femoral vein.
Result:	The distribution to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47-57.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old male Crl:CD(SD) rats
Dosage:	1 mg/kg (Pharmacokinetic Analysis).
Administration:	Via the femoral vein.
Result:	The distribution to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47-57.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (34.28 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.3428 mL	1.7142 mL	3.4285 mL
5 mM	0.0686 mL	0.3428 mL	0.6857 mL
10 mM	0.0343 mL	0.1714 mL	0.3428 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶